Ligandomics: a paradigm shift in biological drug discovery

Wei Li, Iok-Hou Pang, Mario Thiego F. Pacheco, Hong Tian

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

As productivity of pharmaceutical research and development (R&D) for small-molecule drugs declines, the trend in drug discovery strategies is shifting towards biologics, which predominantly target secreted or cell surface proteins. Receptors and ligands are the most-valuable drug targets. In contrast to conventional approaches of discovering one ligand at a time, the emerging technology of ligandomics can systematically map disease-selective cellular ligands in the absence of molecular probes. Biologics targeting these ligands with disease selectivity have the advantages of high efficacy, minimal adverse effects, wide therapeutic indices, and low safety-related attrition rates. Therefore, ligandomics represents a paradigm shift to address the bottleneck of target discovery for biologics development.

Original languageEnglish
Pages (from-to)636-643
Number of pages8
JournalDrug Discovery Today
Volume23
Issue number3
DOIs
StatePublished - 1 Mar 2018

Fingerprint

Drug Discovery
Biological Products
Ligands
Molecular Probes
Therapeutic Uses
Pharmaceutical Preparations
Membrane Proteins
Technology
Safety
Research

Cite this

Li, Wei ; Pang, Iok-Hou ; Pacheco, Mario Thiego F. ; Tian, Hong. / Ligandomics : a paradigm shift in biological drug discovery. In: Drug Discovery Today. 2018 ; Vol. 23, No. 3. pp. 636-643.
@article{3770f1afc7d447db916cb1559e1c6d5f,
title = "Ligandomics: a paradigm shift in biological drug discovery",
abstract = "As productivity of pharmaceutical research and development (R&D) for small-molecule drugs declines, the trend in drug discovery strategies is shifting towards biologics, which predominantly target secreted or cell surface proteins. Receptors and ligands are the most-valuable drug targets. In contrast to conventional approaches of discovering one ligand at a time, the emerging technology of ligandomics can systematically map disease-selective cellular ligands in the absence of molecular probes. Biologics targeting these ligands with disease selectivity have the advantages of high efficacy, minimal adverse effects, wide therapeutic indices, and low safety-related attrition rates. Therefore, ligandomics represents a paradigm shift to address the bottleneck of target discovery for biologics development.",
author = "Wei Li and Iok-Hou Pang and Pacheco, {Mario Thiego F.} and Hong Tian",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.drudis.2018.01.013",
language = "English",
volume = "23",
pages = "636--643",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Ltd",
number = "3",

}

Ligandomics : a paradigm shift in biological drug discovery. / Li, Wei; Pang, Iok-Hou; Pacheco, Mario Thiego F.; Tian, Hong.

In: Drug Discovery Today, Vol. 23, No. 3, 01.03.2018, p. 636-643.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Ligandomics

T2 - a paradigm shift in biological drug discovery

AU - Li, Wei

AU - Pang, Iok-Hou

AU - Pacheco, Mario Thiego F.

AU - Tian, Hong

PY - 2018/3/1

Y1 - 2018/3/1

N2 - As productivity of pharmaceutical research and development (R&D) for small-molecule drugs declines, the trend in drug discovery strategies is shifting towards biologics, which predominantly target secreted or cell surface proteins. Receptors and ligands are the most-valuable drug targets. In contrast to conventional approaches of discovering one ligand at a time, the emerging technology of ligandomics can systematically map disease-selective cellular ligands in the absence of molecular probes. Biologics targeting these ligands with disease selectivity have the advantages of high efficacy, minimal adverse effects, wide therapeutic indices, and low safety-related attrition rates. Therefore, ligandomics represents a paradigm shift to address the bottleneck of target discovery for biologics development.

AB - As productivity of pharmaceutical research and development (R&D) for small-molecule drugs declines, the trend in drug discovery strategies is shifting towards biologics, which predominantly target secreted or cell surface proteins. Receptors and ligands are the most-valuable drug targets. In contrast to conventional approaches of discovering one ligand at a time, the emerging technology of ligandomics can systematically map disease-selective cellular ligands in the absence of molecular probes. Biologics targeting these ligands with disease selectivity have the advantages of high efficacy, minimal adverse effects, wide therapeutic indices, and low safety-related attrition rates. Therefore, ligandomics represents a paradigm shift to address the bottleneck of target discovery for biologics development.

UR - http://www.scopus.com/inward/record.url?scp=85040587109&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2018.01.013

DO - 10.1016/j.drudis.2018.01.013

M3 - Review article

C2 - 29326083

AN - SCOPUS:85040587109

VL - 23

SP - 636

EP - 643

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 3

ER -